Drug Shortage Report for ACYCLOVIR SODIUM INJECTION
| Report ID | 266277 |
| Drug Identification Number | 02236926 |
| Brand name | ACYCLOVIR SODIUM INJECTION |
| Common or Proper name | ACYCLOVIR SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | ACYCLOVIR |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10 mL |
| ATC code | J05AB |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2025-08-31 |
| Estimated end date | 2026-02-09 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-11-17 |
| Company comments | Fresenius Kabi Canada regrets to advise that due an increase in demand from a market shortage, we will be encountering a supply interruption on our Acyclovir Sodium Injection 50 mg/mL, 10 mL Vial effective August 31, 2025, until January 1, 2026. During this time, our Acyclovir Sodium Injection 50 mg/mL, 20 mL Vial is available for substitution in limited quantities.To further support the market shortage, we are pleased to advise that our US-authorized Acyclovir Injection, USP, 500 mg per 10 mL (50 mg per mL) is also available. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2025-11-17 | French | Compare |
| v5 | 2025-11-17 | English | Compare |
| v4 | 2025-09-05 | French | Compare |
| v3 | 2025-09-05 | English | Compare |
| v2 | 2025-09-01 | French | Compare |
| v1 | 2025-09-01 | English | Compare |
Showing 1 to 6 of 6